Results regarding two other variants, p.P350L and c.1002+78A>G, are also noteworthy, i.e., they occur more frequently in individuals who do not have dysfunctional variants of ABCG2. Taking into account that, according to the conclusion of another study, variant c.1002+78A>G reduces the risk of gout, our results suggest that c.1002+78A>G and p.P350L could reduce the risk of hyperuricemia and gout [23]. Here, ABCG2 is linked to hyperuricemia.